Artios Pharma
Artios is a DNA damage response company formed by Cancer Research UK and SV Health Investors in 2016. Artios collaborated with what is now the Cancer Research Horizons' therapeutic innovation division (formerly Therapeutic Discovery Labs) to help develop its lead programmes. A significant milestone for the company was the entry of its ATR inhibitor (ART0380), entering Ph1/2a in patients with advanced or metastatic solid tumours.
Case Study: Taking on DNA repair to tackle cancer: the story from discovery to translation